Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Ovarian cancer risk factors by histologic subtypes and development of an ovarian cancer risk prediction model in the Ovarian Cancer Cohort Consortium (OC3)

Principal Investigator
Name
Nicolas Wentzensen MD
Institution
NCI, DCEG, HREB
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2012-0355
Initial CDAS Request Approval
Aug 9, 2012
Title
Ovarian cancer risk factors by histologic subtypes and development of an ovarian cancer risk prediction model in the Ovarian Cancer Cohort Consortium (OC3)
Summary
Ovarian cancer is the most lethal gynecologic malignancy, accounting for 21,990 new cases and 15,460 deaths in the US in 2011. Although the prognosis for early stage ovarian cancer is excellent, effective early detection strategies have not been developed, and most patients present with fatal late stage tumors that have 5-year survival rates of 30%. The etiology of ovarian cancer is complex and poorly understood, in part because risk factor associations may differ by histologic type, grade and other factors. We previously analyzed ovarian cancer risk factor associations by histologic subtypes in AARP and observed heterogeneity of several risk factor associations (e.g. oral contraceptive use, body mass index) by subtypes. However, case numbers were too low for some categories such as clear cell cancers to establish specific risk factor associations. Thus, analyses of risk factor associations by ovarian cancer heterogeneity can only be studied in consortial efforts with adequate power. Towards this goal, we are establishing an Ovarian Cancer Cohort Consortium (OC3) which currently has about 15 participating, on-going cohort studies with over 5,000 ovarian cancer cases. The OC3 will be the first cohort consortium solely devoted to ovarian cancer. The primary goals of the consortium are to study risk factors of ovarian cancer by subtype, tumor dominance, and tumor fatality, and to develop ovarian cancer risk prediction models accounting for differential associations by cancer phenotype.
Aims

1. Analyze whether associations of risk factors with invasive ovarian cancer, including (but not limited to) age, OCs, tubal ligation, parity, postmenopausal hormone use, family history of ovarian cancer, BMI, height, analgesic use, and lifetime ovulatory cycles, differ by: (a) Histologic subtype. (b) Tumor dominance (as a surrogate for cell of origin) (c) Tumor fatality (tumors fatal within three years vs. all others). 2. Develop ovarian cancer risk prediction models accounting for differential associations by cancer phenotype.

Collaborators

Amanda Black (DCEG, NCI)
Patricia Hartge (DCEG, NCI)
Britton Trabert (DCEG, NCI)

Related Publications
  • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
    Wentzensen N , Poole EM , Trabert B , White E , Arslan AA , Patel AV , Setiawan VW , Visvanathan K , Weiderpass E , Adami HO , Black A , Bernstein L , Brinton LA , Buring J , Butler LM , Chamosa S , Clendenen TV , Dossus L , Fortner R , Gapstur SM , ...show more Gaudet MM , Gram IT , Hartge P , Hoffman-Bolton J , Idahl A , Jones M , Kaaks R , Kirsh V , Koh WP , Lacey JV , Lee IM , Lundin E , Merritt MA , Onland-Moret NC , Peters U , Poynter JN , Rinaldi S , Robien K , Rohan T , Sandler DP , Schairer C , Schouten LJ , Sjöholm LK , Sieri S , Swerdlow A , Tjonneland A , Travis R , Trichopoulou A , van den Brandt PA , Wilkens L , Wolk A , Yang HP , Zeleniuch-Jacquotte A , Tworoger SS
    J. Clin. Oncol. 2016 Aug 20; Volume 34 (Issue 24): Pages 2888-98 PUBMED